Longeveron Reveals Public Offering of Up to $17.5 Million

Longeveron Inc. Announces Upcoming Offering

Potential revenue from a recent offering could reach $12.5 million, with initial amounts estimated around $500,000 before fees are deducted.

On August 8, 2025, Miami-based Longeveron Inc. (NASDAQ: LGVN) revealed it is working on cellular therapies aimed at treating rare pediatric conditions. The company has also introduced short-term warrants that allow for the purchase of up to 14,705,885 shares of Class A common stock at an exercise price of $0.85 per share. These warrants can be exercised immediately and will remain available for 24 months from their issue date. Notably, some board members and insiders are taking part in this offering under the same conditions. The closure of this offering is expected around August 11, 2025.

HC Wainwright & Co. is acting as the exclusive placement agent for this offering.

If fully exercised, these short-term warrants could generate an additional approximate gross revenue of $12.5 million for Longeveron. The company intends to direct any net income from this offering towards ongoing clinical developments, particularly for conditions such as HLHS, Alzheimer’s disease, and pediatric DCM. The funds will also assist in regulatory approvals and necessary activities to support these efforts.

This securities issuance aligns with the registration statement on Form S-1 filed with the Securities and Exchange Commission (SEC) on August 4, 2025. A preliminary prospectus has been submitted to the SEC. Interested parties can access the final prospectus through the SEC’s website or contact HC Wainwright & Co.

About Longeveron Inc.

Longeveron is focused on developing regenerative medicine solutions for unmet medical needs. Their flagship product, Laromestrocel (Lomecel-B™), is derived from mesenchymal stem cells sourced from healthy young adults. Laromestrocel is believed to have several therapeutic benefits, including anti-inflammatory properties and promoting blood vessel growth. Currently, Longeveron is pursuing treatments for HLHS, Alzheimer’s disease, pediatric diastolic cardiomyopathy, and age-related frailty. The company currently holds multiple FDA designations for these projects.

Forward-Looking Statements

This announcement includes forward-looking statements that entail risks and uncertainties. These statements are based on current expectations and assumptions regarding future performance and economic conditions. There are various factors that could cause actual results to deviate significantly from those expressed. These factors include market conditions, capital access difficulties, competition, and the overall regulatory landscape.

For a more in-depth understanding, further details regarding these risks are available in the company’s filings with the SEC, including their annual report and other quarterly documents.